Bernd Meibohm is an Associate Professor of Pharmaceutical Sciences at the College of Pharmacy of the University of Tennessee Health Science Center, Memphis. He obtained his PhD from the University Carolo-Wilhelmina in Braunschweig, Germany, and underwent postdoctoral training in clinical pharmacology at the University of Florida, Gainesville. His research is focused on pharmacokinetics (PK), pharmacodynamics (PD), and pharmacogenetics (PG) with special emphasis on PK/PD/PG correlations. Professor Meibohm is a Fellow of the American College of Clinical Pharmacology (ACCP) and has received numerous awards, including the 'Young Investigator Award in PK, PD and Drug Metabolism' from the American Association of Pharmaceutical Scientists (AAPS) in 2000. He is currently serving as Section Editor for PK and PD for the 'Journal of Clinical Pharmacology' and on the Editorial Boards of the 'Journal of Pediatric Pharmacology and Therapeutics' and 'Die Pharmazie'.

"... There is an urgent need to understand the PK and PD characteristics of these different types of drugs. This book meets that need. ..."Anticancer Research

• The Role of Pharmacokinetics and Pharmacodynamics in the Development of Biotech Drugs Pharmacokinetics of Peptides and Proteins Pharmacokinetics of Monoclonal Antibodies Pharmacokinetics and Pharmacodynamics of Antisense Oligonucleotides Pharmacokinetics of Viral and Non-Viral Gene Delivery Vectors Bioanalytical Methods used for Pharmacokinetic Evaluations of Biotech Macromolecule Drugs: Issues, Assay Approaches, and Limitations Limitations of Noncompartmental Pharmacokinetic Analysis of Biotech Drugs Bioequivalence of Biologics Biopharmaceutical Challenges in Pulmonary Delivery of Proteins and Peptides Biopharmaceutical Challenges: Delivery of Oligonucleotides Custom-Tailored Pharmacokinetics and Pharmacodynamics via Chemical Modifications of Biotech Drugs Exposure-Response Relationships for Therapeutic Biologic Products Preclinical and Clinical Drug Development of Tasidotin, a Depsi-Pentapeptide Oncolytic Agent Clinical Drug Development of Cetuximab, a Monoclonal Antibody Integration of Pharmacokinetics and Pharmacodynamics into the Drug Development of Pegfilgrastim, a Pegylated Protein

Bernd Meibohm is an Associate Professor of Pharmaceutical Sciences at the College of Pharmacy of the University of Tennessee Health Science Center, Memphis. He obtained his PhD from the University Carolo-Wilhelmina in Braunschweig, Germany, and underwent postdoctoral training in clinical pharmacology at the University of Florida, Gainesville. His research is focused on pharmacokinetics (PK), pharmacodynamics (PD), and pharmacogenetics (PG) with special emphasis on PK/PD/PG correlations. Professor Meibohm is a Fellow of the American College of Clinical Pharmacology (ACCP) and has received numerous awards, including the 'Young Investigator Award in PK, PD and Drug Metabolism' from the American Association of Pharmaceutical Scientists (AAPS) in 2000. He is currently serving as Section Editor for PK and PD for the 'Journal of Clinical Pharmacology' and on the Editorial Boards of the 'Journal of Pediatric Pharmacology and Therapeutics' and 'Die Pharmazie'.

"... There is an urgent need to understand the PK and PD characteristics of these different types of drugs. This book meets that need. ..."Anticancer Research

• The Role of Pharmacokinetics and Pharmacodynamics in the Development of Biotech Drugs Pharmacokinetics of Peptides and Proteins Pharmacokinetics of Monoclonal Antibodies Pharmacokinetics and Pharmacodynamics of Antisense Oligonucleotides Pharmacokinetics of Viral and Non-Viral Gene Delivery Vectors Bioanalytical Methods used for Pharmacokinetic Evaluations of Biotech Macromolecule Drugs: Issues, Assay Approaches, and Limitations Limitations of Noncompartmental Pharmacokinetic Analysis of Biotech Drugs Bioequivalence of Biologics Biopharmaceutical Challenges in Pulmonary Delivery of Proteins and Peptides Biopharmaceutical Challenges: Delivery of Oligonucleotides Custom-Tailored Pharmacokinetics and Pharmacodynamics via Chemical Modifications of Biotech Drugs Exposure-Response Relationships for Therapeutic Biologic Products Preclinical and Clinical Drug Development of Tasidotin, a Depsi-Pentapeptide Oncolytic Agent Clinical Drug Development of Cetuximab, a Monoclonal Antibody Integration of Pharmacokinetics and Pharmacodynamics into the Drug Development of Pegfilgrastim, a Pegylated Protein

Bernd Meibohm is an Associate Professor of Pharmaceutical Sciences at the College of Pharmacy of the University of Tennessee Health Science Center, Memphis. He obtained his PhD from the University Carolo-Wilhelmina in Braunschweig, Germany, and underwent postdoctoral training in clinical pharmacology at the University of Florida, Gainesville. His research is focused on pharmacokinetics (PK), pharmacodynamics (PD), and pharmacogenetics (PG) with special emphasis on PK/PD/PG correlations. Professor Meibohm is a Fellow of the American College of Clinical Pharmacology (ACCP) and has received numerous awards, including the 'Young Investigator Award in PK, PD and Drug Metabolism' from the American Association of Pharmaceutical Scientists (AAPS) in 2000. He is currently serving as Section Editor for PK and PD for the 'Journal of Clinical Pharmacology' and on the Editorial Boards of the 'Journal of Pediatric Pharmacology and Therapeutics' and 'Die Pharmazie'.

"... There is an urgent need to understand the PK and PD characteristics of these different types of drugs. This book meets that need. ..."Anticancer Research

• The Role of Pharmacokinetics and Pharmacodynamics in the Development of Biotech Drugs Pharmacokinetics of Peptides and Proteins Pharmacokinetics of Monoclonal Antibodies Pharmacokinetics and Pharmacodynamics of Antisense Oligonucleotides Pharmacokinetics of Viral and Non-Viral Gene Delivery Vectors Bioanalytical Methods used for Pharmacokinetic Evaluations of Biotech Macromolecule Drugs: Issues, Assay Approaches, and Limitations Limitations of Noncompartmental Pharmacokinetic Analysis of Biotech Drugs Bioequivalence of Biologics Biopharmaceutical Challenges in Pulmonary Delivery of Proteins and Peptides Biopharmaceutical Challenges: Delivery of Oligonucleotides Custom-Tailored Pharmacokinetics and Pharmacodynamics via Chemical Modifications of Biotech Drugs Exposure-Response Relationships for Therapeutic Biologic Products Preclinical and Clinical Drug Development of Tasidotin, a Depsi-Pentapeptide Oncolytic Agent Clinical Drug Development of Cetuximab, a Monoclonal Antibody Integration of Pharmacokinetics and Pharmacodynamics into the Drug Development of Pegfilgrastim, a Pegylated Protein